Sustained Cellular and Humoral Immune Responses From an Adenoviral Vector-based Respiratory Syncytial Virus Vaccine
- PMID: 31339994
- DOI: 10.1093/cid/ciz659
Sustained Cellular and Humoral Immune Responses From an Adenoviral Vector-based Respiratory Syncytial Virus Vaccine
Keywords: adenoviral vector; clinical trial; respiratory syncytial virus; vaccine.
Comment on
-
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.Clin Infect Dis. 2020 May 6;70(10):2073-2081. doi: 10.1093/cid/ciz653. Clin Infect Dis. 2020. PMID: 31340042 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
